Skip to main content

Cypress Acquires Personalized Medicine Technology from Cellatope

NEW YORK (GenomeWeb News) – Cypress Bioscience has acquired Cellatope's technology platform for diagnosing and monitoring autoimmune disorders, such as lupus, for up to $5 million.

San Diego-based Cypress said that the technology platform uses cell-bound complement activation products for diagnosis and monitoring of response to treatment. It was developed by researchers at the Lupus center for Excellence at the University of Pittsburgh to evaluate cell-bound fragments of activated complement proteins and their utility in diagnosis and monitoring of lupus patients.

Cypress intends to complete development of the system and offer personalized medicine services to lupus patients. The firm already sells tests for therapeutic monitoring, diagnosis, and prognosis of patients with rheumatoid arthritis.

Cypress paid $2 million in cash to Cellatope for the CB-CAP technology and will make an additional $3 million potential milestone payment based on commercial development of the technology for lupus monitoring.

In connection with the acquisition, Cypress will assume a license from the University of Pittsburgh.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.